Patent: 9,896,502
✉ Email this page to a colleague
Summary for Patent: 9,896,502
Title: | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
Abstract: | The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described. |
Inventor(s): | Bigal; Marcelo (Doylestown, PA), Walter; Sarah (Redwood City, CA), Stern; Henry (Woodside, CA), Chang; Michael (Portola Valley, CA) |
Assignee: | Teva Pharmaceuticals International GmbH (Jona, CH) |
Application Number: | 14/664,715 |
Patent Claims: | see list of patent claims |
Details for Patent 9,896,502
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Teva Branded Pharmaceutical Products R&d, Inc. | AJOVY | fremanezumab-vfrm | Injection | 761089 | 09/14/2018 | ⤷ Try a Trial | 2034-03-21 |
Teva Branded Pharmaceutical Products R&d, Inc. | AJOVY | fremanezumab-vfrm | Injection | 761089 | 01/27/2020 | ⤷ Try a Trial | 2034-03-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,896,502
Country | Patent Number | Estimated Expiration |
---|---|---|
Argentina | 099821 | ⤷ Try a Trial |
Argentina | 119559 | ⤷ Try a Trial |
Australia | 2015230933 | ⤷ Try a Trial |
Brazil | 112016021423 | ⤷ Try a Trial |
Canada | 2943551 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |